Abstract: Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.

Abstract: Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.

Abstract: Packaging comprising a fluorochrome sensitive to visible light placed in a bottle of which at least the side walls form an effective screen against light spectrum radiation between 200 and 900 nm and a process for protecting fluorochromes sensitive to visible light during storage, in which said fluorochromes are placed in a bottle of which at least the side walls form an effective screen against light spectrum radiation between 200 and 900 nm.

Abstract: Oligonucleotides containing the non-palindromic sequence motif:

Abstract: A process for permeabilizing erythrocytes in which the erythrocytes are subjected successively to the action of (a) a fixing agent containing an aliphatic aldehyde and oligosaccharide, (b) a permeabilizing agent containing a detergent and an oligosaccharide, kit for permeabilizing erythrocytes, kit for immuno-marking fetal erythrocytes, and a process for identifying fetal erythrocytes by immuno-marking.

Abstract: Packaging comprising a fluorochrome sensitive to visible light placed in a bottle of which at least the side walls form an effective screen against light spectrum radiation between 200 and 900 nm and a process for protecting fluorochromes sensitive to visible light during storage, in which said fluorochromes are placed in a bottle of which at least the side walls form an effective screen against light spectrum radiation between 200 and 900 nm.

Abstract: A multifunctional reagent for erythrocytes containing an amount sufficient to produce the lysis of erythrocytes or the sphering of erythrocytes in such a way that they can be detected by a cytometer or an automatic counting device, of a carbamate or of an agent inducing the formation by the erythrocytes, from carbonate and from a nitrogenated heterocycle or ammonium ions, of a carbamate combined with the absorption of CO2 by said erythrocytes, process for lysing or sphering erythrocytes and preparation process for leucocytes.

Abstract: A peptide of the formula I X-A-D-Trp-Y wherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophan, &ggr;-aminobutyric acid or &zgr;-aminocaproic acid; A is D-gluptamic acid or D-iso-glutamic acid; and Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophn, &ggr;-aminobutyric acid, &zgr;-aminocaproic acid, hydroxyl, or an amide group.

Abstract: A liquid pharmaceutical formulation for administration by the oro-mucosal route, comprising at least one non-polypeptidic active substance and less than 5% W/W of capryl caproyl macrogol glycerides, process for its preparation and it uses.

Abstract: A peptide of the formula I X-Tyr-Y-Phe-Z-A  I wherein X is hydrogen, arginine, D-arginine, ornithine, D-ornithine, lysine, D-lysine, homoarginine, D-homoarginine, citrulline, D-citrulline; Tyr is tyrosine; Y is D-alanine, D-valine, D-leucine, D-isoleucine, D-phenylalanine, D-asparagine, D-tryptophan, D-proline, D-serine, D-threonine, D-tyrosine, D-hydroxyproline, D-cysteine, D-cysteyl-cysteine, D-methionine, D-lysine, D-homoarginine, D-arginine, D-histidine, D-aspartic acid, D-glutamic acid, D-&bgr;-alanine, or D-ornithine; Phe is phenylalanine; Z is alanine, D-alanine, valine, D-valine, leucine, D-leucine, isoleucine, D-isoleucine, phenylalanine, D-phenylalanine, asparagine, D-asparagine, glycine, glutamine, D-glutamine, tryptophan, D-tryptophan, proline, D-proline, serine, D-serine, threonine, D-threonine, tyrosine, D-tyrosine, hydroxyproline, D-hydroxyproline, cysteine, D-cysteine, cysteyl-cysteine, cysteine-D-cysteine, D-cysteyl-cysteine, D-cysteine-D-cysteine, methionine, D-methionine, lysin

Abstract: A peptide of the formula I X-Tyr-Y-Phe-Z-A  I wherein X is hydrogen, arginine, D-arginine, ornithine, D-ornithine, lysine, D-lysine, homoarginine, D-homoarginine, citrulline, D-citrulline; Tyr is tyrosine; Y is D-alanine, D-valine, D-leucine, D-isoleucine, D-phenylalanine, D-asparagine, D-tryptophan, D-proline, D-serine, D-threonine, D-tyrosine, D-hydroxyproline, D-cysteine, D-cysteyl-cysteine, D-methionine, D-lysine, D-homoarginine, D-arginine, D-histidine, D-aspartic acid, D-glutamic acid, D-&bgr;-alanine, or D-ornithine; Phe is phenylalanine; Z is alanine, D-alanine, valine, D-valine, leucine, D-leucine, isoleucine, D-isoleucine, phenylalanine, D-phenylalanine, asparagine, D-asparagine, glycine, glutamine, D-glutamine, tryptophan, D-tryptophan, proline, D-proline, serine, D-serine, threonine, D-threonine, tyrosine, D-tyrosine, hydroxyproline, D-hydroxyproline, cysteine, D-cysteine, cysteyl-cysteine, cysteine-D-cysteine, D-cysteyl-cysteine, D-cysteine-D-cysteine, methionine, D-methionine, lysin

Abstract: A peptide of the formula IX--Glu--Trp--Y (I)wherein X is H or Gly, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid, .xi.-aminocaproic acid, and Y is Gly, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid, .xi.-aminocaproic acid, --OH, mono- or di-substituted amide (c.sub.1 -c.sub.3) and the uses therefore in modulating the immune system and hemopiesis.

Abstract: The lysis of erythrocytes is accomplished by subjecting whole blood treated with an anticoagulant at a pH between 4 and 9 with a nitrogenous heterocyclic compound, most preferably pyrrolidine chloride.

Abstract: A peptide of the formula IX--A--D--Trp--Ywherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophan, .gamma.-aminobutyric acid or .xi.-aminocaproic acid; A is D-gluptamic acid or D-iso-glutamic acid; and Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophn, .gamma.-aminobutyric acid, .xi.-aminocaproic acid, hydroxyl, or an amide group.

Abstract: The invention relates to medicine, specifically, to methods of obtaining biologically active substances with immuno-regulating properties, and can be used in medicine and veterinary science and in experimental biochemistry. The fundamental problem addressed by the invention is that of producing a noval synthetic biologically active peptide with immuno-regulating properties and of the formula: X-Glu-Trp-Y, in which X is H or Gly, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid, .zeta.-aminocapronic acid; Y is Gla, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid .zeta.-aminocapronic acid, --OH, NH.sub.2,N.sub.2 H.sub.3, mono- or di-substituted amide (C.sub.1 -C.sub.3).

Abstract: A method for reducing cancerous tumors is disclosed. The method includes administering to a mammal an effective amount of epinephrine. In another embodiment, the mammal is immediately immobilized after receiving injections of epinephrine. In a most preferred embodiment, the method also includes administering an effective amount of a cardioselective adrenergic blocking agent prior to administering of epinephrine.

Abstract: A polyclonal or monoclonal antibody recognizing specifically cortisol in a urine medium produced by immunization of animals against an immunogen compound composed of the hapten cortisol-3-carboxymethyloxime (syn isomer), coupled by its carboxyl function to a macromolecule, an immunoasay process for cortisol, particularly urinary cortisol, an assay kit and novel derivatives of coritsol.

Abstract: Process for the identification or assay of a particular polypeptide antigen X in which an immunological determination of the presence of said polypeptide antigen X is carried out in a sample, characterized in that the sample is treated in vitro using at least one chemical reagent reactingon an epsilon -NH.sub.2 function of a lysine residue oron a terminal alpha -NH.sub.2 function of a peptidein order to carry out the linking of said reagent to said polypeptide antigen X and in this way to obtain a modified polypeptide antigen X, (polypeptide antigen Xm), the immunological determination of the presence of said polypeptide antigen X in said sample is then carried out using at least one antibody produced by immunization against a polypeptide antigen Y identical to the polypeptide antigen Xm or to an antigenic fragment of this antigen Xm.

Abstract: Soluble, single chain T cell receptors, nucleic acid sequences, particularly DNA sequences, encoding the soluble, single chain T cell receptor, expression vectors containing the DNA sequences, and host cells containing the expression vectors.

Abstract: A preparation for lysing erythrocytes, characterized herein so far as the aqueous preparation with a substantially physiological ionic strength comprising a mixture:of an aliphatic aldehyde,of a polyhydric alcohol and,of a salt of a strong acid and of an alkali metal or an alkaline earth metal.